Meropenil (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious infections caused by Gram‑negative and Gram‑positive bacteria.

• Complicated intra‑abdominal infections: effective in eliminating polymicrobial pathogens and reducing infection‑related mortality.
• Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: provides coverage against resistant organisms and improves clinical cure rates.
• Complicated urinary tract infections: eradicates resistant Enterobacteriaceae and restores urinary sterility.
• Bacterial meningitis: penetrates the cerebrospinal fluid to achieve therapeutic concentrations and treat central nervous system infections.

• Meropenem binds to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This blockade weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its high affinity for multiple PBPs and resistance to most β‑lactamases underlies its activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms, both in vitro and in vivo.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal discomfort occurring in many patients.
• Diarrhea: loose stools that may be self‑limiting.
• Rash: skin erythema or mild urticaria.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Seizures: risk increases with high doses or renal dysfunction.
• Anaphylaxis: acute hypersensitivity reaction requiring immediate treatment.
• Clostridioides difficile‑associated colitis: severe diarrhea due to intestinal flora disruption.
• Neutropenia: marked reduction in white blood cells leading to infection risk.

When using Meropenem, several precautions should be observed to ensure safe and effective therapy.

• Renal function: adjust dose in patients with impaired clearance.
• Seizure risk: monitor patients with central nervous system disorders or receiving high doses.
• Allergy: avoid in patients with known β‑lactam hypersensitivity.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Concurrent nephrotoxic drugs: monitor renal parameters closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Valproic acid: concomitant use may reduce serum valproate levels, risking seizure breakthrough.
• Probenecid: may increase meropenem concentrations, enhancing toxicity.
• High‑dose aminoglycosides: combined nephrotoxicity risk.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may affect renal clearance, requiring monitoring.
• Anticonvulsants (e.g., carbamazepine): may lower seizure threshold when meropenem induces neurotoxicity.
• Oral contraceptives: possible reduction in efficacy, advise alternative contraception.